HIV 1 News and Research

RSS

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded contracts to three organizations to support early-stage human clinical trials of investigational infectious disease treatments. The new awards for the Phase I Clinical Trial Units for Therapeutics increases the number of funded organizations under the program from two to three, expanding capacity for conducting early safety testing of novel investigational drugs.

15 Jan 2015

HIV/AIDS survival rates lower in the southern U.S.

The southern U.S. had the nation's lowest five-year survival rate among those diagnosed with HIV or AIDS in 2003-2004, according to new research.

15 Jan 2015

UH Case Medical Center, ABL partner to design and validate HIV drug resistance tests

University Hospitals Case Medical Center has signed an agreement with Advanced Biological Laboratories, an information technology and diagnostic company based in Luxembourg, to join efforts on the designing and validation of an HIV drug resistance and tropism assay based on next-generation sequencing (NGS).

14 Jan 2015

Injectable hormonal contraceptive appears to increase HIV risk in women

Women using depot medroxyprogesterone acetate (DMPA), commonly known as Depo-Provera or the birth control shot, have a moderately increased risk of becoming infected with HIV, a large meta-analysis of 12 studies involving more than 39 500 women published in The Lancet Infectious Diseases has found. Other forms of hormonal contraception, including oral contraceptive pills, do not appear to increase this risk.

12 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.

8 Jan 2015

Johns Hopkins-led study offers strategy to eradicate HIV

Luring dormant HIV out of hiding and destroying its last cure-defying holdouts has become the holy grail of HIV eradication, but several recent attempts to do so have failed. Now the findings of a Johns Hopkins-led study reveal why that is and offer a strategy that could form a blueprint for a therapeutic vaccine to eradicate lingering virus from the body.

8 Jan 2015

Using HIV drugs to treat AMD: an interview with Dr Mark Young

NRTIs are compounds which were originally developed in the 1960s as anti-cancer agents. They are similar in structure to the bases which make up DNA, and it was hoped that they would interfere with DNA replication in fast-growing cancer cells, slowing down or stopping tumour growth.

7 Jan 2015

Real-time RT-PCR TaqMan assay helps differentiate active pulmonary TB from LTBI

One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.

7 Jan 2015

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.

29 Dec 2014

Medical researchers at Saint Louis University bring hope to those in pain and sickness

This year, Saint Louis University medical researchers advanced their fields, contributing to human knowledge and bringing hope to those in pain and sickness.

23 Dec 2014

Cell-associated HIV transmission contributes to HIV epidemic

Dr. Deborah Anderson from Boston University School of Medicine (BUSM) and her colleagues are challenging dogma about the transmission of the human immunodeficiency virus type 1 (HIV-1).

22 Dec 2014

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis.

21 Dec 2014

SLU investigators find promising candidates for new herpes virus treatments

Saint Louis University research findings published in the December issue of Antimicrobial Agents and Chemotherapy report a family of molecules known as nucleotidyltransferase superfamily (NTS) enzyme inhibitors are promising candidates for new herpes virus treatments.

19 Dec 2014

Certain complementary medicines may cause side effects, warns NPS MedicineWise

With new information from Melbourne’s Peter MacCallum Cancer Centre revealing that some complementary medicines can interact with cancer treatment, NPS MedicineWise reminds all Australians that complementary medicines can cause side effects, and interact with other over-the-counter and prescription medicines.

19 Dec 2014

New analysis finds global improvements in life expectancy

Global life expectancy increased by 5.8 years in men and 6.6 years in women between 1990 and 2013, according to a major new analysis from the Global Burden of Disease Study 2013 (GBD 2013).

19 Dec 2014

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157.

18 Dec 2014

Researchers identify a single protein as root cause of multiple allergic reactions

Johns Hopkins and University of Alberta researchers have identified a single protein as the root of painful and dangerous allergic reactions to a range of medications and other substances. If a new drug can be found that targets the problematic protein, they say, it could help smooth treatment for patients with conditions ranging from prostate cancer to diabetes to HIV

17 Dec 2014

Researchers find new 'sliding scale' model to rule out blood clots in lungs

Researchers from Intermountain Medical Center in Salt Lake City have identified a new "sliding scale" model used to rule out potentially deadly blood clots in the lungs, known as pulmonary embolisms, that is more accurate than current diagnostic methods.

17 Dec 2014

EGPAF to receive $63 million UNITAID grant to improve early infant diagnosis of HIV programs

The Elizabeth Glaser Pediatric AIDS Foundation is pleased to announce that it has been selected by the UNITAID Executive Board to receive up to $63 million in funding to improve early infant diagnosis (EID) of HIV programs in nine African countries. This investment will pave the way for universal access to HIV testing and enable a ten-fold increase in HIV treatment, thus transforming the effort to end AIDS in children worldwide.

17 Dec 2014

New intervention combines social media with behavioral psychology to encourage more HIV testing

Social media such as Twitter and Facebook can be valuable in the fight against HIV in the United States, where research has demonstrated they can prompt high-risk populations to request at-home testing kits for the virus that causes AIDS, suggesting a way to potentially boost testing rates.

17 Dec 2014

HIV 1 News and Research

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

HIV/AIDS survival rates lower in the southern U.S.

UH Case Medical Center, ABL partner to design and validate HIV drug resistance tests

Injectable hormonal contraceptive appears to increase HIV risk in women

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

Johns Hopkins-led study offers strategy to eradicate HIV

Using HIV drugs to treat AMD: an interview with Dr Mark Young

Real-time RT-PCR TaqMan assay helps differentiate active pulmonary TB from LTBI

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Medical researchers at Saint Louis University bring hope to those in pain and sickness

Cell-associated HIV transmission contributes to HIV epidemic

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

SLU investigators find promising candidates for new herpes virus treatments

Certain complementary medicines may cause side effects, warns NPS MedicineWise

New analysis finds global improvements in life expectancy

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Researchers identify a single protein as root cause of multiple allergic reactions

Researchers find new 'sliding scale' model to rule out blood clots in lungs

EGPAF to receive $63 million UNITAID grant to improve early infant diagnosis of HIV programs

New intervention combines social media with behavioral psychology to encourage more HIV testing

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News